Get the latest news, insights, and market updates on IOVA (Iovance Biotherapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Is Iovance Biotherapeutics (IOVA) Undervalued? A Fresh Look at Valuation After Recent Share Price Rebound
Iovance Biotherapeutics (IOVA) stock has had a mixed performance recently, catching the eye of investors who are interested in how biotech names recover over time. Its latest trading sessions reflect cautious optimism as the sector continues to experience ongoing shifts. See our latest analysis for Iovance Biotherapeutics. Iovance Biotherapeutics shares have made a dramatic comeback in recent days, with a 1-day share price return of 27.62 percent that builds on recent momentum. Still, the... Nov 7, 2025 - $IOVA
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
Quarterly Revenue Growth of 13% to ~$68 Million Gross Margin Increased to 43% on Improved Execution and Operational Efficiency Best-in-Class Clinical Profile for Lifileucel in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) with Median Duration of Response Not Reached after 25+ Months Follow Up SAN CARLOS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering nove Nov 6, 2025 - $IOVA
Dynavax Technologies (DVAX) Surpasses Q3 Earnings Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +50.00% and -0.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 5, 2025 - $IOVA
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced interim data from its registr Nov 3, 2025 - $IOVA
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
SAN CARLOS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter 2025 financial results and corporate updates before market on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update Oct 23, 2025 - $IOVA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple